NORCROSS,SpectRx has received another $1.1 million grant from the National Cancer Institute for development of its non-invasive cervical cancer detection technology.

SpectRx, which announced the grant on Tuesday, has received $2.5 million in all from the NCI for the program.

A subsidiary of SpectRx, Guided Therapeutics, is commercializing the product.

In its grant approval, the NCI said: “Contrary to existing standards such as the Pap test, if successful, the proposed device will offer a rapid and accurate point-of-care diagnostic test for cervical cancer. This is an important topic and the results of the proposed work could have a significant effect on improving the current practice and accuracy of cervical caner diagnosis and/or screening.”

The device uses proprietary technology involving light reflected from the cervix for cancer detection.

SpectRx: www.spectrx.com